IASLC World Conference on Lung Cancer | Conference

Dato-DXd Leads to Intracranial Responses in Advanced/Metastatic NSCLC With Brain Metastases

September 8th 2025

Dato-DXd demonstrated CNS PFS and ORR benefits vs docetaxel in patients with NSCLC with brain metastases.

Concurrent Durvalumab and Chemoradiotherapy Fails to Provide Survival Advantage in Unresectable, Stage III NSCLC

September 8th 2025

Durvalumab/chemoradiation followed by consolidation durvalumab did not improve OS vs chemoradiation followed by durvalumab in stage III NSCLC.

Taletrectinib Demonstrates Durable Responses in TKI-Naive and -Pretreated ROS1+ NSCLC

September 8th 2025

Taletrectinib delivered high response rates and durable benefit with manageable safety in ROS1-positive non–small cell lung cancer.

Perioperative Pembrolizumab Plus Chemo Yields Improved Survival, Responses in Early-Stage Resectable NSCLC

September 8th 2025

Perioperative pembrolizumab demonstrated improved mPR, pCR, EFS, and OS in patients with early-stage resectable NSCLC and any nodal status.

Adjuvant Nivolumab Plus Chemo Decreases Disease Relapse Rates vs Chemo in Resected NSCLC

September 8th 2025

Adjuvant nivolumab plus chemotherapy led to a clinically meaningful reduction in relapse rates vs chemotherapy in resected NSCLC.

Ifinatamab Deruxtecan Elicits Responses in Previously Treated Extensive-Stage Small Cell Lung Cancer

September 7th 2025

Ifinatamab deruxtecan was efficacious and had a manageable safety profile in patients with previously treated extensive-stage small cell lung cancer.

Zidesamtinib Data Align With Clinical Expectations in Pretreated ROS1+ Advanced NSCLC

September 7th 2025

The brain-penetrant, TRK-sparing, ROS1-selective TKI zidesamtinib was active and safe in patients with advanced ROS1+ non–small cell lung cancer.

Ivonescimab Plus Chemo After Third-Generation TKI Generates Improved PFS in EGFR-Mutated NSCLC

September 7th 2025

Ivonescimab plus chemotherapy showed significant and clinically meaningful PFS in EGFR-mutated NSCLC following progression on a third-generation TKI.

Dr Liu on Updated Efficacy and Safety Data With Taletrectinib in ROS1+ NSCLC

September 7th 2025

Geoffrey Liu, MSc, MD, discusses updated efficacy and safety results with taletrectinib in ROS1-positive non–small cell lung cancer.

Dr Drilon on the Efficacy of Zidesamtinib Relative to Other ROS1 Inhibitors in Pretreated ROS1+ NSCLC

September 7th 2025

Alexander Drilon, MD, compares response rates with zidesamtinib with that of prior ROS1 inhibitors in pretreated patients with ROS1-positive NSCLC.

Adjuvant Crizotinib Fails to Produce DFS, OS Benefit Over Observation in Resected ALK+ NSCLC

September 7th 2025

Results from the ALCHEMIST trial show that adjuvant crizotinib did not improve DFS or OS vs observation in resected ALK-positive NSCLC.

Frontline Osimertinib Plus Chemo Significantly Improves OS in EGFR-Mutated Advanced NSCLC

September 7th 2025

Updated FLAURA2 OS data confirm osimertinib plus chemotherapy as a first-line SOC treatment in EGFR-mutated advanced NSCLC.

Aumolertinib Plus Chemotherapy Improves PFS in EGFR-Mutated NSCLC

September 7th 2025

The addition of aumolertinib to chemotherapy improved PFS vs aumolertinib monotherapy for the treatment of patients with EGFR-mutated NSCLC.

CheckMate 77T QOL Data Further Support Perioperative Nivolumab in Resectable NSCLC

September 7th 2025

Perioperative nivolumab maintained HRQOL and decreased the risk of deterioration vs placebo in patients with stage III N2 NSCLC.

Continuing Osimertinib Plus Chemo After Progression Improves PFS in EGFR-Mutated NSCLC

September 6th 2025

COMPEL data support osimertinib plus chemotherapy in EGFR-mutated NSCLC after non-CNS progression on frontline osimertinib.

Frontline Iza-Bren Plus Osimertinib Elicits 100% ORR in EGFR-Mutant NSCLC

September 6th 2025

First-line iza-bren plus osimertinib demonstrated a manageable safety profile with preliminary antitumor activity in EGFR-mutant NSCLC.

Experts Highlight Key Topics to Watch at the IASLC 2025 World Conference on Lung Cancer

August 28th 2025

Experts preview key abstracts to watch at the IASLC 2025 World Conference on Lung Cancer.

Experts Highlight Top Findings From the 2024 IASLC World Conference on Lung Cancer

September 18th 2024

Experts across the lung cancer treatment space impart their key takeaways from research shared at the 2024 IASLC World Conference on Lung Cancer.

Dr Hiltermann on ARTEMIDE-01 Data With Rilvegostomig in Metastatic NSCLC

September 11th 2024

T. Jeroen N. Hiltermann, MD, discusses findings from phase 1/2 ARTEMIDE-01 trial.

Amivantamab Plus Lazertinib Delays Symptomatic Progression in EGFR+ Advanced NSCLC

September 11th 2024

Patients with EGFR-mutated NSCLC demonstrated reduced symptom progression when treated with amivantamab plus lazertinib vs osimertinib.